From https://www.news-medical.net/news/2...everses-biological-age-in-clinical-study.aspx
Title : AI-designed drug candidate reverses biological age in clinical study
By Insilico Medicine , Sept 2026
... Insilico announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University .. Recently published in Nature Biotechnology, the study represents the first clinical evaluation of a potentially first-in-class drug candidate featuring both an AI-discovered target with relevance to aging and disease biology and an AI-designed molecule ... (go to the link for details of the drug)
Recently, Insilico reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing (in HK, Dez 2025), with an adjusted net profit exceeding $51 million. This milestone was driven by a series of out-licensing, co-development, and R&D collaborations with global partners, including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the latest practicable date, the total contract value of transactions announced by Insilico in 2026 reached approximately $7.3 billion, pushing the cumulative contract value of its major collaborations since 2021 to approximately $11 billion ...
the majority of Insilico's 40+ drug programs have dual purpose targeting aging and disease in a broad range of therapeutic areas ...
Title : AI-designed drug candidate reverses biological age in clinical study
By Insilico Medicine , Sept 2026
... Insilico announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University .. Recently published in Nature Biotechnology, the study represents the first clinical evaluation of a potentially first-in-class drug candidate featuring both an AI-discovered target with relevance to aging and disease biology and an AI-designed molecule ... (go to the link for details of the drug)
Recently, Insilico reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing (in HK, Dez 2025), with an adjusted net profit exceeding $51 million. This milestone was driven by a series of out-licensing, co-development, and R&D collaborations with global partners, including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS, and Tenacia. As of the latest practicable date, the total contract value of transactions announced by Insilico in 2026 reached approximately $7.3 billion, pushing the cumulative contract value of its major collaborations since 2021 to approximately $11 billion ...
the majority of Insilico's 40+ drug programs have dual purpose targeting aging and disease in a broad range of therapeutic areas ...
